Public Announcement of Financial Results of the 7th Fiscal Year and Capital Reduction
Tokyo (March 23rd, 2022)-, Cellusion Inc. a regenerative medicine startup aiming to solve the global Corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells (CECSi Cells) for bullous keratopathy novel treatment (PJ code: CLS001), today announced the public announcement of the 7th fiscal year financial results and the public announcement of the capital reduction in the Official Gazette dated March 23, 2022 (Issue No. 59, p. 92).
Please click here for details.
For further information: please ask us through the contact form on our website.